259 related articles for article (PubMed ID: 32745161)
1. Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis.
Marchetti MA; Coit DG; Dusza SW; Yu A; McLean L; Hu Y; Nanda JK; Matsoukas K; Mancebo SE; Bartlett EK
JAMA Dermatol; 2020 Sep; 156(9):953-962. PubMed ID: 32745161
[TBL] [Abstract][Full Text] [Related]
2. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
Grossman D; Okwundu N; Bartlett EK; Marchetti MA; Othus M; Coit DG; Hartman RI; Leachman SA; Berry EG; Korde L; Lee SJ; Bar-Eli M; Berwick M; Bowles T; Buchbinder EI; Burton EM; Chu EY; Curiel-Lewandrowski C; Curtis JA; Daud A; Deacon DC; Ferris LK; Gershenwald JE; Grossmann KF; Hu-Lieskovan S; Hyngstrom J; Jeter JM; Judson-Torres RL; Kendra KL; Kim CC; Kirkwood JM; Lawson DH; Leming PD; Long GV; Marghoob AA; Mehnert JM; Ming ME; Nelson KC; Polsky D; Scolyer RA; Smith EA; Sondak VK; Stark MS; Stein JA; Thompson JA; Thompson JF; Venna SS; Wei ML; Swetter SM
JAMA Dermatol; 2020 Sep; 156(9):1004-1011. PubMed ID: 32725204
[TBL] [Abstract][Full Text] [Related]
4. Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.
Greenhaw BN; Covington KR; Kurley SJ; Yeniay Y; Cao NA; Plasseraud KM; Cook RW; Hsueh EC; Gastman BR; Wei ML
J Am Acad Dermatol; 2020 Sep; 83(3):745-753. PubMed ID: 32229276
[TBL] [Abstract][Full Text] [Related]
5. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC
Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242
[TBL] [Abstract][Full Text] [Related]
6. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study.
Dillon LD; McPhee M; Davidson RS; Quick AP; Martin B; Covington KR; Zolochevska O; Cook RW; Vetto JT; Jarell AD; Fleming MD
Curr Med Res Opin; 2022 Aug; 38(8):1267-1274. PubMed ID: 35081854
[TBL] [Abstract][Full Text] [Related]
7. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
[TBL] [Abstract][Full Text] [Related]
8. Expert Consensus on the Use of Prognostic Gene Expression Profiling Tests for the Management of Cutaneous Melanoma: Consensus from the Skin Cancer Prevention Working Group.
Farberg AS; Marson JW; Glazer A; Litchman GH; Svoboda R; Winkelmann RR; Brownstone N; Rigel DS;
Dermatol Ther (Heidelb); 2022 Apr; 12(4):807-823. PubMed ID: 35353350
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling in melanoma: past results and future potential.
Knackstedt RW; Knackstedt T; Gastman B
Future Oncol; 2019 Mar; 15(7):791-800. PubMed ID: 30453756
[TBL] [Abstract][Full Text] [Related]
10. Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma.
Dubin DP; Dinehart SM; Farberg AS
Am J Clin Dermatol; 2019 Dec; 20(6):763-770. PubMed ID: 31359351
[TBL] [Abstract][Full Text] [Related]
11. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
Eggermont AMM; Bellomo D; Arias-Mejias SM; Quattrocchi E; Sominidi-Damodaran S; Bridges AG; Lehman JS; Hieken TJ; Jakub JW; Murphree DH; Pittelkow MR; Sluzevich JC; Cappel MA; Bagaria SP; Perniciaro C; Tjien-Fooh FJ; Rentroia-Pacheco B; Wever R; van Vliet MH; Dwarkasing J; Meves A
Eur J Cancer; 2020 Nov; 140():11-18. PubMed ID: 33032086
[TBL] [Abstract][Full Text] [Related]
12. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
[TBL] [Abstract][Full Text] [Related]
13. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test.
Mirsky R; Prado G; Svoboda R; Glazer A; Rigel D
J Drugs Dermatol; 2018 Nov; 17(11):1220-1223. PubMed ID: 30500144
[TBL] [Abstract][Full Text] [Related]
14. Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies.
Dhillon S; Duarte-Bateman D; Fowler G; Hagstrom MNE; Lampley N; Olivares S; Fumero-Velázquez MS; Vu K; Wayne JD; Gastman BR; Vetto J; Gerami P
Arch Dermatol Res; 2023 Oct; 315(8):2295-2302. PubMed ID: 36977840
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma.
Hsueh EC; DeBloom JR; Lee JH; Sussman JJ; Covington KR; Caruso HG; Quick AP; Cook RW; Slingluff CL; McMasters KM
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036233
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients.
Scoggins CR; Martin RC; Ross MI; Edwards MJ; Reintgen DS; Urist MM; Gershenwald JE; Sussman JJ; Dirk Noyes R; Goydos JS; Beitsch PD; Ariyan S; Stromberg AJ; Hagendoorn LJ; McMasters KM
Ann Surg Oncol; 2010 Mar; 17(3):709-17. PubMed ID: 19967459
[TBL] [Abstract][Full Text] [Related]
17. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.
Gastman BR; Gerami P; Kurley SJ; Cook RW; Leachman S; Vetto JT
J Am Acad Dermatol; 2019 Jan; 80(1):149-157.e4. PubMed ID: 30081113
[TBL] [Abstract][Full Text] [Related]
18. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
Amaral T; Sinnberg T; Chatziioannou E; Niessner H; Leiter U; Keim U; Forschner A; Dwarkasing J; Tjien-Fooh F; Wever R; Flatz L; Eggermont A; Forchhammer S
Eur J Cancer; 2023 Mar; 182():155-162. PubMed ID: 36739215
[TBL] [Abstract][Full Text] [Related]
19. CORRELATION OF GENE EXPRESSION PROFILE STATUS AND AMERICAN JOINT COMMISSION ON CANCER STAGE IN UVEAL MELANOMA.
Berry DE; Schefler AC; Seider MI; Materin M; Stinnett S; Mruthyunjaya P;
Retina; 2020 Feb; 40(2):214-224. PubMed ID: 31972790
[TBL] [Abstract][Full Text] [Related]
20. Predictive accuracy of risk prediction models for recurrence, metastasis and survival for early-stage cutaneous melanoma: a systematic review.
Kunonga TP; Kenny RPW; Astin M; Bryant A; Kontogiannis V; Coughlan D; Richmond C; Eastaugh CH; Beyer FR; Pearson F; Craig D; Lovat P; Vale L; Ellis R
BMJ Open; 2023 Sep; 13(9):e073306. PubMed ID: 37770261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
